Company Overview - Evommune is developing next-generation therapies for chronic inflammation, which contributes to 3 out of 5 deaths worldwide[8] - The annual direct cost of chronic inflammation is at least $90 billion[9] - Evommune completed a $173 million IPO in November 2025 and has approximately $235 million in cash and investments as of September 30, 2025[115, 116] Clinical Programs - Evommune has two Phase 2 programs: EVO756 (oral MRGPRX2 antagonist) and EVO301 (long-acting IL-18 fusion protein)[15, 117] - EVO756 is being developed for chronic spontaneous urticaria (CSU) and atopic dermatitis (AD)[20, 117] - EVO301 is being developed for atopic dermatitis and ulcerative colitis[20, 117] - Three Phase 2 data readouts are expected in 2026: EVO756 in CSU (H1 2026), EVO756 in AD (H2 2026), and EVO301 in AD (H1 2026)[20, 117] EVO756 Clinical Data - In a Phase 2 trial in chronic inducible urticaria (CIndU), both 300 mg QD and 50 mg BID doses of EVO756 demonstrated robust clinical activity, with 30% of patients achieving a complete response after just 4 weeks[47, 49] - In the CIndU trial, at week 4, patients on 300 mg QD (N=10) saw a 14 point reduction and 50 mg BID patients (N=17) saw a 15 point reduction in Mean FricTest Score (0-4)[52] EVO756 Phase 2b Trials - A Phase 2b dose-ranging trial in CSU (N = 160) is underway, with topline data expected in H1 2026[72] - A Phase 2b dose-ranging trial in AD (N = 120) is underway, with topline data expected in H2 2026[80]

Core Insights - Eight new stocks were listed last week, including one direct listing company, raising significant capital across various sectors [1][2][3]. Group 1: Recent IPOs - MapLight Therapeutics (MPLT) raised $251 million by issuing 14.75 million shares at $17 each [1]. - Navan (NAVN) raised $923 million by issuing 36.92 million shares at $25 each [1]. - Boyd Group Services (BGSI) raised $780 million by issuing 5.5 million shares at $141 each [2]. - Nomadar (NOMA) entered Nasdaq through a direct listing [3]. Group 2: Upcoming IPOs - BETA Technologies, Inc. plans to list on NYSE with a target date of November 4, 2025, aiming to raise approximately $825 million by issuing 25 million shares at $27 to $33 each. The company reported revenue of $15.57 million in the first half of 2025, up from $7.59 million in the same period last year, with a net loss of $159 million [4][6]. - Exzeo Group, Inc. plans to list on NYSE on November 5, 2025, aiming to raise about $176 million by issuing 8 million shares at $20 to $22 each. The company reported revenue of $109 million in the first half of 2025, up from $60.31 million year-over-year, with a net profit of $39.61 million [6][8]. - Evommune, Inc. plans to list on NYSE on November 6, 2025, aiming to raise approximately $159 million by issuing 9.38 million shares at $15 to $17 each. The company reported revenue of $3 million in the first half of 2025, down from $7 million year-over-year, with a net loss of $28.12 million [10]. - Grupo Aeroméxico, S.A.B. de C.V. plans to list on NYSE on November 6, 2025, aiming to raise about $235 million by issuing 11.73 million shares at $18 to $20 each. The company reported revenue of $2.498 billion in the first half of 2025, down from $2.695 billion year-over-year, with a net profit of $89.97 million [12]. - BillionToOne, Inc. plans to list on NASDAQ on November 6, 2025, aiming to raise approximately $212 million by issuing 3.85 million shares at $49 to $55 each. The company reported revenue of $126 million in the first half of 2025, up from $69.09 million year-over-year, with a net loss of $4.23 million [14]. - Off The Hook YS Inc. plans to list on NYSE MKT on November 7, 2025, aiming to raise about $30 million by issuing 5 million shares at $4 to $6 each. The company reported revenue of $58.59 million in the first half of 2025, up from $51.85 million year-over-year, with a net profit of $840,000 [16].

Core Points - Evommune, Inc. has filed a registration statement for an initial public offering (IPO) of its common stock, offering 9,375,000 shares at an expected price between $15.00 and $17.00 per share [1] - The company plans to grant underwriters a 30-day option to purchase an additional 1,406,250 shares in connection with the IPO [1] - Evommune's common stock is expected to be listed on the New York Stock Exchange under the symbol "EVMN" [1] - The registration statement is anticipated to become effective on November 5, 2025, allowing the company to price the offering shortly thereafter [1] - Morgan Stanley, Leerink Partners, Evercore ISI, and Cantor are acting as joint book-running managers for the proposed offering [2] Company Overview - Evommune, Inc. is a clinical-stage biotechnology company focused on developing innovative therapies targeting chronic inflammatory diseases [5] - The company's mission is to enhance patients' daily lives and mitigate long-term effects of uncontrolled inflammation caused by existing therapy limitations [5] - Evommune is advancing a portfolio of differentiated product candidates aimed at addressing key drivers of chronic inflammation [5]

Group 1 - Evommune, a biotech company focused on therapies for chronic inflammatory diseases, announced its IPO terms, aiming to raise $150 million by offering 9.4 million shares at a price range of $15 to $17 [1] - The company's lead candidate, EVO756, is a potent and selective MRGPRX2 oral small molecule antagonist for chronic spontaneous urticaria (CSU) and atopic dermatitis (AD), currently in a Phase 2b trial with results expected in the second half of 2026 [1] - Evommune's second candidate, EV0301, is a long-acting fusion protein for treating atopic dermatitis (AD) and ulcerative colitis (UC), with plans to initiate a Phase 2 trial for moderate to severe UC patients in 2026 [1] Group 2 - Founded in 2020, Evommune reported revenue of $3 million for the 12 months ending June 30, 2025, and plans to list on the New York Stock Exchange under the ticker "EVMN" [2] - The company has appointed Morgan Stanley, Leerink Partners, Evercore ISI, and Cantor Fitzgerald as joint book-running managers for the IPO, with the final pricing expected during the week of November 3, 2025 [2]

Core Viewpoint - Evommune, a biotechnology company focused on developing therapies for chronic inflammatory diseases, has filed for an IPO to raise up to $100 million [1][2] Company Overview - Evommune is headquartered in Palo Alto, California, and was founded in 2020 [2] - The company reported revenue of $3 million for the 12 months ending June 30, 2025 [2] - The company plans to list on the New York Stock Exchange under the ticker symbol EVMN [2] Product Pipeline - The core candidate drug, EVO756, is a potent and selective oral small molecule MRGPRX2 antagonist aimed at treating chronic spontaneous urticaria (CSU) and atopic dermatitis (AD) [1] - Another investigational drug, EV0301, is a long-acting fusion protein designed for the treatment of atopic dermatitis (AD) and ulcerative colitis (UC) [1] - Evommune has initiated a Phase 2b clinical trial for EVO756, with results expected in the second half of 2026 [1] - The company plans to start a Phase 2 clinical trial for moderate to severe ulcerative colitis (UC) patients in 2026 [1] IPO Details - The IPO application was submitted to the SEC on Thursday, with plans to raise up to $100 million [1] - The joint book-running managers for the offering include Morgan Stanley, Leerink Partners, Evercore ISI, and Cantor Fitzgerald [2] - The pricing terms for the offering have not yet been disclosed [2]